Developer docs
API playgroundTry for free, no card

Search company profiles

Alpine Immune Sciences

Full company profile

uuid000375d

Namestring
Alpine Immune Sciences
Legal namestring
Alpine Immune Sciences
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Alpine Immune Sciences was a Seattle-based clinical-stage biopharmaceutical company developing protein-based immunotherapies for autoimmune and inflammatory diseases. Founded in 2015 and publicly listed on NASDAQ under the ticker ALPN from 2017, the company operated with 51-100 employees at its Seattle headquarters and was incorporated in Washington, USA. During its independent existence, the company had no commercial products on the market and served end-patient populations with autoimmune and inflammatory conditions, with particular focus on IgA nephropathy (IgAN), an indication affecting approximately 1.5 million people worldwide.

The company's lead asset was povetacicept, a dual BAFF/APRIL inhibitor characterized as a pipeline-in-a-product candidate. In the Phase 3 RAINIER trial, povetacicept demonstrated a 52% reduction in urine protein over 36 weeks compared to 4.3% for placebo, supporting its potential as a significant therapy for IgA nephropathy. Analysts estimated the renal franchise could exceed $10 billion in peak sales. The company raised approximately $474 million cumulatively across venture and post-IPO equity rounds between 2015 and 2023, with lead investors including Frazier Healthcare Partners, OrbiMed, and Decheng Capital. Leadership included co-founder and Executive Chairman Mitchell Gold, President Jay Venkatesan, Chief Business Officer Remy Durand, and Chief Medical Officer Wolfgang Dummer.

Alpine's business model was a capital-markets-funded, pre-commercial R&D model: the company raised public and private equity to advance its clinical pipeline, generated no product revenue, and had no commercial distribution or marketing channels. In 2024, Vertex Pharmaceuticals acquired Alpine Immune Sciences for approximately $4.9 billion in cash at $65 per share, with the acquisition unanimously approved by both company boards. Following the acquisition, Alpine Immune Sciences ceased operating as an independent entity and became a wholly-owned subsidiary of Vertex Pharmaceuticals, a Boston-based diversified biotech company.

Short descriptiontext

Alpine Immune Sciences was a Seattle-based clinical-stage biopharmaceutical company developing povetacicept, a dual BAFF/APRIL inhibitor for IgA nephropathy and other autoimmune diseases. The company was pre-revenue, raised over $474 million across multiple funding rounds, and was acquired by Vertex Pharmaceuticals in 2024 for $4.9 billion.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immunotherapy development, autoimmune disease therapeutics, IgA nephropathy treatment, biopharmaceutical drug development, protein engineering platform
Industry3 codes
PRIMARYHLAAAAAI
Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Immunotherapy
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Alpine Immune Sciences was a clinical-stage biopharmaceutical company developing novel immunotherapies for autoimmune and inflammatory diseases. Its lead asset, povetacicept, is a dual BAFF/APRIL inhibitor being advanced for IgA nephropathy (IgAN) and other autoimmune indications. The company was acquired by Vertex Pharmaceuticals in 2024 for approximately $4.9 billion, reflecting the asset's clinical and commercial potential demonstrated in the Phase 3 RAINIER trial.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 52% reduction in urine protein versus 4.3% for placebo over 36 weeks in Phase 3 RAINIER trial
+2 more records
Product overview1 text field

Alpine Immune Sciences was a Seattle-based biotech company that went public in 2017 and was developing drugs for autoimmune and inflammatory diseases. The company's primary asset was povetacicept, a pipeline-in-a-product candidate for IgA nephropathy and potentially other autoimmune indications. The company was acquired by Vertex Pharmaceuticals in 2024 for approximately $4.9 billion before any commercial product launch.

Product and service1 record
1Povetacicept
CategoryDrug candidate / Biologic therapy
Description

Povetacicept is a pipeline-in-a-product biologic drug candidate (a dual BAFF/APRIL inhibitor) being developed for the treatment of IgA nephropathy (IgAN) and other autoimmune and inflammatory diseases. It demonstrated a 52% reduction in urine protein versus 4.3% for placebo over 36 weeks in the Phase 3 RAINIER trial.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Vertex Pharmaceuticals acquired Alpine Immune Sciences for approximately $4.9 billion in cash at $65 per share. The acquisition was unanimously approved by both company boards and completed in 2024. Vertex gained access to Alpine's key asset povetacicept, a pipeline-in-a-product for IgA nephropathy and other autoimmune diseases.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Develops sparsentan (Filspari, with Otsuka) for IgA nephropathy and FSGS. Direct competitor in IgAN with an active commercial product and overlapping prescriber base.

TypeEmerging player
Description

Commercial-stage immunology biotech with FcRn-targeted therapies (e.g., VYVGART) for autoimmune diseases. Comparable as a developer of innovative biologics for autoimmune indications with similar commercial-stage profiles.

TypeDirect peer
Description

Develops narsoplimab for IgA nephropathy and other complement/inflammation-mediated diseases. Competes in the same IgAN patient population and nephrology prescriber channel.

4Bristol Myers Squibb
TypeBroad incumbent
Description

Major immunology franchise (e.g., Zeposia, Sotyktu) with overlapping R&D focus in autoimmune and inflammatory diseases, including active IgAN-adjacent programs.

TypeBroad incumbent
Description

Acquired Alpine in 2024 for ~$4.9B; the most directly comparable large-cap acquirer in the IgAN/autoimmune biologic space and now the strategic steward of Povetacicept.

TypeBroad incumbent
Description

Commercializes sparsentan (Filspari) in IgAN through a partnership with Travere. A larger incumbent nephrology/specialty pharma with direct overlap on Alpine's lead indication.

TypeDirect peer
Description

Commercial-stage biopharma whose lead product Tarpeyo is approved for IgA nephropathy. Direct therapeutic-area competitor to Alpine's Povetacicept and the most relevant precedent for commercial launch in IgAN.

TypeDirect peer
Description

Late-stage clinical biotech developing atacicept, a dual BAFF/APRIL inhibitor for IgA nephropathy. Mechanism-overlap competitor to Povetacicept and a direct comparator asset in the same indication.

TypeDirect peer
Description

Pre-acquisition by Novartis, Chinook was a kidney-disease biotech with late-stage IgAN and rare renal assets — a directly comparable targeted-rare-nephrology developer to Alpine.

TypeDirect peer
Description

Commercial-stage developer of voclosporin (Lupkynis) for lupus nephritis, with adjacency to IgAN and rare autoimmune kidney disease — comparable target physicians, payers, and regulatory pathway.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alpine Immune Sciences

Biopharmaceutical Immunotherapyalpineimmunesciences.com

Alpine Immune Sciences was a Seattle-based clinical-stage biopharmaceutical company developing povetacicept, a dual BAFF/APRIL inhibitor for IgA nephropathy and other autoimmune diseases. The company was pre-revenue, raised over $474 million across multiple funding rounds, and was acquired by Vertex Pharmaceuticals in 2024 for $4.9 billion.

What Alpine Immune Sciences does

Alpine Immune Sciences was a Seattle-based clinical-stage biopharmaceutical company developing protein-based immunotherapies for autoimmune and inflammatory diseases. Founded in 2015 and publicly listed on NASDAQ under the ticker ALPN from 2017, the company operated with 51-100 employees at its Seattle headquarters and was incorporated in Washington, USA. During its independent existence, the company had no commercial products on the market and served end-patient populations with autoimmune and inflammatory conditions, with particular focus on IgA nephropathy (IgAN), an indication affecting approximately 1.5 million people worldwide.

The company's lead asset was povetacicept, a dual BAFF/APRIL inhibitor characterized as a pipeline-in-a-product candidate. In the Phase 3 RAINIER trial, povetacicept demonstrated a 52% reduction in urine protein over 36 weeks compared to 4.3% for placebo, supporting its potential as a significant therapy for IgA nephropathy. Analysts estimated the renal franchise could exceed $10 billion in peak sales. The company raised approximately $474 million cumulatively across venture and post-IPO equity rounds between 2015 and 2023, with lead investors including Frazier Healthcare Partners, OrbiMed, and Decheng Capital. Leadership included co-founder and Executive Chairman Mitchell Gold, President Jay Venkatesan, Chief Business Officer Remy Durand, and Chief Medical Officer Wolfgang Dummer.

Alpine's business model was a capital-markets-funded, pre-commercial R&D model: the company raised public and private equity to advance its clinical pipeline, generated no product revenue, and had no commercial distribution or marketing channels. In 2024, Vertex Pharmaceuticals acquired Alpine Immune Sciences for approximately $4.9 billion in cash at $65 per share, with the acquisition unanimously approved by both company boards. Following the acquisition, Alpine Immune Sciences ceased operating as an independent entity and became a wholly-owned subsidiary of Vertex Pharmaceuticals, a Boston-based diversified biotech company.

Alpine Immune Sciences firmographics

Firmographics
Name
Alpine Immune Sciences
Legal name
Alpine Immune Sciences
Website
https://alpineimmunesciences.com
Company type
Public
Founded year
2017
Operating status
Acquired
Headcount range
11–50 employees
Short description
Alpine Immune Sciences was a Seattle-based clinical-stage biopharmaceutical company developing povetacicept, a dual BAFF/APRIL inhibitor for IgA nephropathy and other autoimmune diseases. The company was pre-revenue, raised over $474 million across multiple funding rounds, and was acquired by Vertex Pharmaceuticals in 2024 for $4.9 billion.
Ownership category
akta.pro rank

Alpine Immune Sciences industry classification

Industry
Product category
Biopharmaceutical Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAI
Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Immunotherapy development
  • Autoimmune disease therapeutics
  • IgA nephropathy treatment
  • Biopharmaceutical drug development
  • Protein engineering platform

Where Alpine Immune Sciences is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Alpine Immune Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Alpine Immune Sciences product offering

Product offering

Core offering

Alpine Immune Sciences was a clinical-stage biopharmaceutical company developing novel immunotherapies for autoimmune and inflammatory diseases. Its lead asset, povetacicept, is a dual BAFF/APRIL inhibitor being advanced for IgA nephropathy (IgAN) and other autoimmune indications. The company was acquired by Vertex Pharmaceuticals in 2024 for approximately $4.9 billion, reflecting the asset's clinical and commercial potential demonstrated in the Phase 3 RAINIER trial.

Product overview

Alpine Immune Sciences was a Seattle-based biotech company that went public in 2017 and was developing drugs for autoimmune and inflammatory diseases. The company's primary asset was povetacicept, a pipeline-in-a-product candidate for IgA nephropathy and potentially other autoimmune indications. The company was acquired by Vertex Pharmaceuticals in 2024 for approximately $4.9 billion before any commercial product launch.

Differentiator

Problem solved

Functional benefit

Products and services

  • Povetacicept Povetacicept is a pipeline-in-a-product biologic drug candidate (a dual BAFF/APRIL inhibitor) being developed for the treatment of IgA nephropathy (IgAN) and other autoimmune and inflammatory diseases. It demonstrated a 52% reduction in urine protein versus 4.3% for placebo over 36 weeks in the Phase 3 RAINIER trial.

Quantifiable outcome

  • 52% reduction in urine protein versus 4.3% for placebo over 36 weeks in Phase 3 RAINIER trial
  • +2 more outcomes

Companies that use Alpine Immune Sciences

Customer profile

Segments1 record

Ideal customer profiles2 records

Alpine Immune Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Alpine Immune Sciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Vertex PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2024Vertex Pharmaceuticals acquired Alpine Immune Sciences for approximately $4.9 billion in cash at $65 per share. The acquisition was unanimously approved by both company boards and completed in 2024. Vertex gained access to Alpine's key asset povetacicept, a pipeline-in-a-product for IgA nephropathy and other autoimmune diseases.

Scale indicators4 records

Recent moves10 records

Expansion highlights4 records

Alpine Immune Sciences competitors and assessment

Company assessment

Direct peers

  • Travere Therapeutics: Develops sparsentan (Filspari, with Otsuka) for IgA nephropathy and FSGS. Direct competitor in IgAN with an active commercial product and overlapping prescriber base.
  • Omeros Corporation: Develops narsoplimab for IgA nephropathy and other complement/inflammation-mediated diseases. Competes in the same IgAN patient population and nephrology prescriber channel.
  • Calliditas Therapeutics: Commercial-stage biopharma whose lead product Tarpeyo is approved for IgA nephropathy. Direct therapeutic-area competitor to Alpine's Povetacicept and the most relevant precedent for commercial launch in IgAN.
  • Vera Therapeutics: Late-stage clinical biotech developing atacicept, a dual BAFF/APRIL inhibitor for IgA nephropathy. Mechanism-overlap competitor to Povetacicept and a direct comparator asset in the same indication.
  • Chinook Therapeutics: Pre-acquisition by Novartis, Chinook was a kidney-disease biotech with late-stage IgAN and rare renal assets — a directly comparable targeted-rare-nephrology developer to Alpine.
  • Aurinia Pharmaceuticals: Commercial-stage developer of voclosporin (Lupkynis) for lupus nephritis, with adjacency to IgAN and rare autoimmune kidney disease — comparable target physicians, payers, and regulatory pathway.

Emerging players

  • argenx: Commercial-stage immunology biotech with FcRn-targeted therapies (e.g., VYVGART) for autoimmune diseases. Comparable as a developer of innovative biologics for autoimmune indications with similar commercial-stage profiles.

Broad incumbents

  • Bristol Myers Squibb: Major immunology franchise (e.g., Zeposia, Sotyktu) with overlapping R&D focus in autoimmune and inflammatory diseases, including active IgAN-adjacent programs.
  • Vertex Pharmaceuticals: Acquired Alpine in 2024 for ~$4.9B; the most directly comparable large-cap acquirer in the IgAN/autoimmune biologic space and now the strategic steward of Povetacicept.
  • Otsuka Pharmaceutical: Commercializes sparsentan (Filspari) in IgAN through a partnership with Travere. A larger incumbent nephrology/specialty pharma with direct overlap on Alpine's lead indication.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Alpine Immune Sciences social profiles

Digital presence

Alpine Immune Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alpine Immune Sciences leadership team

Management profile

Number of profiles

Profiles7 records

Alpine Immune Sciences funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alpine Immune Sciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alpine Immune Sciences

What does Alpine Immune Sciences do?

Alpine Immune Sciences was a clinical-stage biopharmaceutical company developing novel immunotherapies for autoimmune and inflammatory diseases. Its lead asset, povetacicept, is a dual BAFF/APRIL inhibitor being advanced for IgA nephropathy (IgAN) and other autoimmune indications. The company was acquired by Vertex Pharmaceuticals in 2024 for approximately $4.9 billion, reflecting the asset's clinical and commercial potential demonstrated in the Phase 3 RAINIER trial.

Is Alpine Immune Sciences a public or private company?

Alpine Immune Sciences is a public company. It is classified as corporate owned and is currently acquired.

When was Alpine Immune Sciences founded?

Alpine Immune Sciences was founded in 2017. It employs 11 to 50 people.

Where is Alpine Immune Sciences based?

Alpine Immune Sciences is headquartered in Seattle, United States, in the North America region.

Who are Alpine Immune Sciences's main competitors?

Direct peers on record are Travere Therapeutics, Omeros Corporation, Calliditas Therapeutics, Vera Therapeutics, Chinook Therapeutics and Aurinia Pharmaceuticals. argenx is listed as an emerging player. Broad incumbents are Bristol Myers Squibb, Vertex Pharmaceuticals and Otsuka Pharmaceutical.

Does Alpine Immune Sciences have an API?

No public API is recorded for Alpine Immune Sciences.

What industry is Alpine Immune Sciences in?

Alpine Immune Sciences's product category is Biopharmaceutical Immunotherapy. Its primary akta.pro industry code is HLAAAAAI, Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors), with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Frazier Life Sciences Raises More Than $1.1 Billion For Public Biotech Fund, Bringing Commitments To $2.8 BillionFrazier Life Sciences raised over $1.1 billion in new commitments for its public biotech fund, bringing total committed capital to about $2.8 billion. The fund targets small- and mid-cap public biotech companies, with Verona Pharma and Alpine Immune Sciences among its largest historical holdings.BioSpaceFrazier adds $1.1B+ to small and mid-sized biotech fundFrazier Life Sciences raised over $1.1 billion in new commitments for its public small- and mid-cap biotech fund, bringing total capital to roughly $2.8 billion. The fund has backed companies like Verona Pharma and Alpine Immune Sciences, which were acquired for $10 billion and $4.9 billion respectively.Business Wire BlogFrazier Life Sciences Adds Over $1.1 Billion to Frazier Life Sciences Public FundFrazier Life Sciences closed over $1.1 billion in capital commitments to its Public Fund, bringing total committed capital to approximately $2.8 billion. The fund, launched in 2021, targets small- and mid-cap public biotech companies and has acquired Verona Pharma and Alpine Immune Sciences.GlobeNewswireIgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsightThe IgA nephropathy market is projected to grow from $1.5 billion in 2025 to a higher value by 2036 at an 18.6% CAGR, driven by rising prevalence and novel therapies. The pipeline includes Phase III candidates like povetacicept and atacicept, with approvals such as VOYXACT already in place.BioSpace5 biopharma M&A deals where the workforce was the prizeMajor pharmaceutical companies have completed five significant biotech acquisitions totaling over $19 billion, where retaining the target company's workforce and expertise was as strategically important as acquiring the assets and pipelines. Gilead Sciences bought German ADC biotech Tubulis for $5 billion, Biogen acquired Apellis Pharmaceuticals for $5.6 billion to gain kidney disease launch expertise, AstraZeneca purchased Canadian radiopharma company Fusion Pharmaceuticals for $2.4 billion and French rare disease biotech Amolyt Pharma for $1.06 billion, while Vertex Pharmaceuticals acquired Alpine Immune Sciences for $4.9 billion to obtain the pipeline-in-a-product asset povetacicept. The article notes an emerging trend where acquiring companies specifically target talent and teams, rather than just assets, with Galapagos CEO also discussing workforce retention as a key negotiating point in potential acquisitions.pharmaphorumVertex preps FDA filing for IgAN drug after phase 3 readoutVertex Pharmaceuticals has reported positive Phase 3 results for povetacicept in treating IgA nephropathy, showing a 52% reduction in protein in urine versus 4.3% for placebo over 36 weeks, with the company preparing to file for FDA accelerated approval by month-end. The drug was acquired as part of Vertex's $4.9 billion takeover of Alpine Immune Sciences in 2024 and has potential in other autoimmune indications. Investors responded positively, driving Vertex's share price up 8% to nearly $500 and pushing its valuation toward $127 billion.TokenistVertex (VRTX) Stock Climbs Premarket After Late-Stage Kidney Drug SuccessVertex Pharmaceuticals announced that its experimental kidney disease drug povetacicept successfully met its primary endpoint in the Phase 3 RAINIER trial, with patients achieving a 52% reduction in urine protein after 36 weeks compared to just 4.3% for placebo, driving the stock up approximately 11% in after-hours trading. The drug, acquired through Vertex's $4.9 billion purchase of Alpine Immune Sciences in 2024, targets IgA nephropathy affecting approximately 1.5 million people worldwide and was generally well tolerated across the 605-patient study. Vertex plans to submit a full FDA application by the end of March using a priority review voucher, with analysts estimating the renal franchise could exceed $10 billion in peak sales.BostonGlobe.comVertex rises after kidney drug meets goal in late-stage trialVertex Pharmaceuticals Inc. announced that its drug povetacicept met its trial goal for treating a kidney disorder, leading to an 11% stock increase. The company plans to submit the drug for FDA approval and use an accelerated review process, following its $4.9 billion acquisition of Alpine Immune Sciences Inc.Clarkston Consulting2025 M&A Deal Trends in Life SciencesThe life sciences sector is experiencing a surge in M&A activity driven by strategic acquisitions in oncology, immunology, and AI-driven drug discovery. Major transactions include Merck's acquisition of Harpoon Therapeutics for $680 million and Vertex Pharmaceuticals' purchase of Alpine Immune Sciences for $4.9 billion to expand their respective pipelines.